-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Attovia Therapeutics, Raises Price Target to $34

Benzinga·11/10/2026 20:09:10
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Attovia Therapeutics (NASDAQ:ATTO) with a Buy and raises the price target from $30 to $34.